OPDIVO (Nivolumab) Drug Pipeline Research Report 2024: The First-in-human Immunoglobulin G4 (IgG4) PD-1 Immune Checkpoint Inhibitor Antibody - Market Size, Forecast, and Emerging Insights 2019-2032 - ResearchAndMarkets.com
The "OPDIVO Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about OPDIVO for ovarian cancer in the six major markets. A detailed picture of the OPDIVO for ovarian cancer in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the OPDIVO for ovarian cancer.
The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the OPDIVO market forecast analysis for ovarian cancer in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
Drug Summary
OPDIVO (also known as Nivolumab) is the first-in-human immunoglobulin G4 (IgG4) PD-1 immune checkpoint inhibitor antibody that disrupts the interaction of the PD-1 receptor with its ligands PD-L1 and PD-L2, thereby inhibiting the cellular immune response. Targeted immunotherapy has now become the most promising approach for tumor patients. PD-1 expressed on activated T-cells can reverse immune suppression and release T-cell activation.
Nivolumab is an already established drug and is currently approved in different indications and for different patient segments. Currently, the drug is being developed in a Phase II (NCT02873962) clinical study evaluating the drug in relapsed epithelial ovarian cancer.
OPDIVO Analytical Perspective
In-depth OPDIVO Market Assessment
This report provides a detailed market assessment of OPDIVO for ovarian cancer in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom. This segment of the report provides forecasted sales data from 2026 to 2032.
OPDIVO Clinical Assessment
The report provides the clinical trials information of OPDIVO for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
- In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OPDIVO dominance.
- Other emerging products for ovarian cancer are expected to give tough market competition to OPDIVO and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OPDIVO in ovarian cancer.
- Our in-depth analysis of the forecasted sales data of OPDIVO from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the OPDIVO in ovarian cancer.
Key Questions Answered
- What is the product type, route of administration and mechanism of action of OPDIVO?
- What is the clinical trial status of the study related to OPDIVO in ovarian cancer and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OPDIVO development?
- What are the key designations that have been granted to OPDIVO for ovarian cancer?
- What is the forecasted market scenario of OPDIVO for ovarian cancer?
- What are the forecasted sales of OPDIVO in the six major countries, including the United States, Europe (Germany, France, Italy, Spain), and the United Kingdom?
- What are the other emerging products available and how are these giving competition to OPDIVO for ovarian cancer?
- Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?
Key Topics Covered:
1. Report Introduction
2. OPDIVO Overview in ovarian cancer
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. OPDIVO Market Assessment
5.1. Market Outlook of OPDIVO in ovarian cancer
5.2. 6MM Analysis
5.2.1. Market Size of OPDIVO in the 6MM for ovarian cancer
5.3. Country-wise Market Analysis
5.3.1. Market Size of OPDIVO in the United States for ovarian cancer
5.3.2. Market Size of OPDIVO in Germany for ovarian cancer
5.3.3. Market Size of OPDIVO in France for ovarian cancer
5.3.4. Market Size of OPDIVO in Italy for ovarian cancer
5.3.5. Market Size of OPDIVO in Spain for ovarian cancer
5.3.6. Market Size of OPDIVO in the United Kingdom for ovarian cancer
6. SWOT Analysis
7. Analysts' Views
8. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/upycop
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
These press releases may also interest you
|
News published on and distributed by:
